Aurinia says ISS recommends holders vote for company’s board nominees

Aurinia Pharmaceuticals Inc. announced that leading independent proxy advisor Institutional Shareholder Services has recommended that Aurinia shareholders vote FOR the re-election of all eight incumbent directors to the Board of Directors at the Company’s 2023 Annual General Meeting. ISS’ positive recommendation follows an April 26 report from Glass Lewis, another leading independent proxy advisor, which also recommended that shareholders vote for the re-election of all incumbent directors. "Aurinia is pleased that ISS and Glass Lewis recognize the Board and management’s pivotal role in the Company’s continued growth and momentum," the company said. "Aurinia’s Board also appreciates the feedback and continued strong support of our shareholders."